On-Chip Clonal Analysis of Glioma-Stem-Cell Motility and Therapy Resistance

Area of Science:

• Biotechnology
• Cancer Research
• Neuro-oncology

Background:

• Glioma-stem-cell (GSC) motility and therapy resistance are critical factors in tumor dissemination and recurrence.
• Understanding these mechanisms is essential for developing more effective glioblastoma treatments.

Purpose of the Study:

• To introduce a novel micro-/nanotechnology-enabled chip platform for live-cell interrogation of patient-derived GSCs.
• To analyze intertumoral and interclonal variations in GSC motility and therapy resistance with single-clone resolution.

Main Methods:

• Development and application of a micro-/nanotechnology-enabled chip platform for live-cell analysis.
• On-chip interrogation of patient-derived GSCs, including motility profiling and therapy resistance studies.
• Correlation of chip-based findings with tumor-xenograft experiments and gene-expression analyses.

Main Results:

• Significant intertumoral differences (>10-fold) in single-clone GSC motility were observed.
• Pronounced interclonal variations (up to ~4-fold) in motility and gene expression were found in aggressive GSCs.
• A subpopulation of CD44-high GSCs exhibited enhanced motility and antiapoptotic behavior under chemotherapy (temozolomide) and anti-miR363 treatment.

Conclusions:

• The developed chip platform allows for unprecedented large-scale, single-cell resolution monitoring of heterogeneous cancer cell populations.
• This technology provides novel insights into the mechanisms of GSC dissemination and therapy resistance.
• The findings highlight the heterogeneity of GSCs and identify specific subpopulations with implications for treatment resistance.